The Next Generation Drug Conjugates Market: Focus on GalNac Conjugate, Peptide Drug Conjugate, Peptide Oligonucleotide Conjugate, RNAi Conjugate, Peptide Receptor Radionuclide Therapy, Small Molecule-Drug Conjugate (SMDC), and Other Conjugates – Distribution by Type of Targeting Ligand (Amino Sugar, Lipid, Peptide, Small Molecule and Virus-like Particles), Type of Payload (Peptide, Small Molecule, Oligonucleotide and Radionuclide), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Subcutaneous and Others), Mechanism of Action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others) and Key Target Indications (Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Primary Hyperoxaluria, Heterozygous Familial Hypercholesterolemia, Hemophilia, Low-Risk Myelodysplastic Syndrome, Myelofibrosis, Alpha-1 Antitrypsin Deficiency Liver Disease and Familial Chylomicronemia Syndrome) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
The global next generation drug conjugate market is anticipated to be valued at USD 15.47 billion in 2035 anticipated to grow at a CAGR of 18% during the forecast period 2023-2035.
The next generation drug conjugates, distinguished by reduced immune reactions, improved clinical traits, stable structures, minimized side effects, precise treatment delivery, enhanced cell penetration, and permeability, shows promise in tackling rare diseases, particularly cancers. In 2020, US rare disease medical expenses surged to nearly USD 1 trillion, with patients spending an average of USD 60,248—twice the amount for general patients. This escalating healthcare cost, coupled with the global burden of rare diseases, has prompted stakeholders to explore alternatives, and these advanced drug conjugates emerge as a hopeful solution.
Similar to antibody drug conjugates (ADCs), these advanced versions boast superior clinical efficacy and stability while employing diverse non-antibody targeting agents such as peptides, amino sugars, lipids, and small molecules. Instead of traditional drugs, they utilize payloads like oligonucleotides, antisense oligonucleotides, si-RNA, drugs, and radionuclides for targeted delivery. This fusion of targeting ligands and payloads has spawned various types of next generation drug conjugates, including peptide drug conjugates, peptide receptor radionuclide therapy, GalNac conjugates, si-RNA conjugates, all proving effective against diseases like solid tumors, metabolic disorders, and hematological disorders.
The USFDA has greenlit six next generation drug conjugates for therapeutic use—Lutathera®, Pluvicto®, Givlaari®, Oxlumo®, Leqvio®, and Amvuttra®. These approvals underscore the clinical triumphs of these advanced therapies and their potential across a wide range of medical conditions. With ongoing innovation, promising trial outcomes, expedited approvals, and collaborative efforts, the market for next generation drug conjugates anticipates significant growth in the forecast period.
Report Coverage
The next generation drug conjugates, distinguished by reduced immune reactions, improved clinical traits, stable structures, minimized side effects, precise treatment delivery, enhanced cell penetration, and permeability, shows promise in tackling rare diseases, particularly cancers. In 2020, US rare disease medical expenses surged to nearly USD 1 trillion, with patients spending an average of USD 60,248—twice the amount for general patients. This escalating healthcare cost, coupled with the global burden of rare diseases, has prompted stakeholders to explore alternatives, and these advanced drug conjugates emerge as a hopeful solution.
Similar to antibody drug conjugates (ADCs), these advanced versions boast superior clinical efficacy and stability while employing diverse non-antibody targeting agents such as peptides, amino sugars, lipids, and small molecules. Instead of traditional drugs, they utilize payloads like oligonucleotides, antisense oligonucleotides, si-RNA, drugs, and radionuclides for targeted delivery. This fusion of targeting ligands and payloads has spawned various types of next generation drug conjugates, including peptide drug conjugates, peptide receptor radionuclide therapy, GalNac conjugates, si-RNA conjugates, all proving effective against diseases like solid tumors, metabolic disorders, and hematological disorders.
The USFDA has greenlit six next generation drug conjugates for therapeutic use—Lutathera®, Pluvicto®, Givlaari®, Oxlumo®, Leqvio®, and Amvuttra®. These approvals underscore the clinical triumphs of these advanced therapies and their potential across a wide range of medical conditions. With ongoing innovation, promising trial outcomes, expedited approvals, and collaborative efforts, the market for next generation drug conjugates anticipates significant growth in the forecast period.
Report Coverage
- An executive summary of the key insights captured during our research, offering a high-level view on the current state of the next generation drug conjugates market and its likely evolution in the short to mid and long term.
- A general overview of the next generation drug conjugates, highlighting their historical background, as well as information on their structure, advantages, and the pharmacokinetic properties of the various next generation drug conjugates, such as GalNac conjugates, peptide drug conjugates and others.
- Information on more than 200 next generation drug conjugates / next generation targeted therapeutics that are either approved or being evaluated in different stages of development (clinical or pre-clinical), based on several relevant parameters, such as type of conjugate (GalNac conjugate, peptide drug conjugate, peptide oligonucleotide conjugate, RNAi conjugate, peptide radionuclide conjugate, small molecule drug conjugate, and other conjugates), type of targeting ligand (amino sugar, lipid, peptide, small molecule and virus-like particles), type of payload, type of biological target, mechanism of action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others), stage of development (preclinical, clinical and approved), phase of development (approved, phase III, phase II, phase I, preclinical and discovery), type of therapy (monotherapy and combination therapy), route of administration (intravenous, subcutaneous and others), target disease indication (muscular dystrophy, lung cancer, hepatitis, breast cancer, nonalcoholic steatohepatitis, prostate cancer, ovarian cancer, hypertension and hypertriglycedermia), therapeutic area (cardiovascular disorders, genetic disorders, hepatic disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, respiratory disorders, renal disorders, and other disorders) and target population (children, adults and older adults). In addition, the chapter features information on various next generation drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of drug candidates).
- Elaborated profiles of leading next generation drug conjugate companies (shortlisted based on number of drug candidates in pipeline that have been approved / commercialized or in Phase III of development) and their respective product portfolios. Each profile features a brief overview of the company, product portfolio, an overview of the drug candidates which are either approved or are in phase III stage of clinical development, along with recent developments, and an informed future outlook of the developer.
- An in-depth analysis of completed, ongoing, and planned clinical studies of various next generation drug conjugates, based on several relevant parameters, such as trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, age group, most active industry players, leading drug candidate, primary purpose, therapeutic area and key geographical regions.
- An in-depth analysis of partnerships that have been inked between various stakeholders since 2018, covering product development and commercialization agreement, research and development agreement, service agreement, platform / technology licensing agreement, acquisition, clinical trial agreement, product licensing agreement, joint ventures and others.
- Grants that have been awarded to research institutes engaged in conducting research related to next generation drug conjugates, since 2018, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (based on number of grants awarded), prominent program officers, leading recipient organizations and key regions.
- An in-depth analysis of more than 400 peer-reviewed, scientific articles focused on next generation drug conjugates that have been published since 2018, based on year of publication, type of publication, number of publications, type of conjugate, target indication and copyright holders. The chapter also highlights the leading publishers and key journals (in terms of number of articles published and impact factor).
- A comprehensive analysis of the next generation drug conjugates that failed to progress to later stages of clinical development, based on various relevant parameters, such as trial status of discontinuation, trial phase of discontinuation, average trial year, type of therapy, target indication and reason for drug failure.
- Insightful success protocol analysis of recently approved and commercialized next generation drug conjugates, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, drug designation, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
- An elaborate market forecast analysis, highlighting the likely growth of the next generation drug conjugates market, till the year 2035. In order to provide details on future opportunity, our projections have been segmented on the basis of type of conjugate (peptide receptor radionuclide therapy, ligand mediated RNAi conjugates, ligand conjugates anti sense medicine and peptide drug conjugates), key target indications (gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, primary hyperoxaluria, heterozygous familial hypercholesterolemia, hemophilia, low-risk myelodysplastic syndrome, myelofibrosis, alpha-1 antitrypsin deficiency liver disease and familial chylomicronemia syndrome), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).
- Advanced Accelerator Applications
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Dicerna Pharmaceuticals
- Geron Corporation
- Ionis Pharmaceuticals
1. PREFACE
1.1. Next Generation Drug Conjugates Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Next Generation Drug Conjugates
3.2. Key Historical Events
3.3. Structure of Next Generation Drug Conjugates
3.4. Biochemical Interaction and Mechanism of Action
3.5. Key Target Indications
3.6. Advantages of Next Generation Drug Conjugates
3.7 Challenges associated with Next Generation Drug Conjugates
3.8. Future Perspectives
4. MARKET LANDSCAPE
4.1. Methodology
4.2. Next Generation Drug Conjugates: List of Therapies
4.2.1. Analysis by Type of Conjugate
4.2.2. Analysis by Type of Targeting Ligand
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Stage of Development
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Type of Therapy
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Target Population
4.2.13. Analysis by Type of Conjugate and Stage of Development
4.2.14. Analysis by Type of Conjugate and Target Populatio
4.3 Next Generation Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.3.6. Most Active Players: Analysis by Number of Drug Candidates
5. COMPANY AND DRUG PROFILES
5.1. Advanced Accelerator Applications
5.1.1. Company Overview
5.1.2. Management Team
5.1.3. Product Portfolio
5.1.3.1. Lutathera®
5.1.3.1.1 Drug Overview
5.1.3.1.2. Clinical Trial Information
5.1.3.1.3. Clinical Trial Results
5.1.3.1.4. Dosing Regimen
5.1.3.1.5. Estimated Sales
5.1.3.2. Pluvicto®
5.1.3.2.1 Drug Overview
5.1.3.2.2. Clinical Trial Information
5.1.3.2.3. Clinical Trial Results
5.1.3.2.4. Dosing Regimen
5.1.3.2.5. Estimated Sales
5.1.4. Recent Developments and Future Outlook
5.2. Alnylam Pharmaceuticals
5.2.1. Company Overview
5.2.2. Management Team
5.2.3. Product Portfolio
5.2.3.1. Givlaari®
5.2.3.1.1. Drug Overview
5.2.3.1.2. Clinical Trial Information
5.2.3.1.3. Clinical Trial Results
5.2.4.1.4. Dosing Regimen
5.2.3.2. Oxlumo®
5.2.3.2.1. Drug Overview
5.2.3.2.2. Clinical Trial Information
5.2.3.2.3. Clinical Trial Results
5.2.3.2.4. Dosing Regimen
5.2.3.3. Leqvio®
5.2.3.3.1. Drug Overview
5.2.3.3.2. Clinical Trial Information
5.2.3.3.3. Clinical Trial Results
5.2.3.3.4. Dosing Regimen
5.2.3.4. Amvuttra®
5.2.3.4.1. Drug Overview
5.2.3.4.2. Clinical Trial Information
5.2.3.4.3. Clinical Trial Results
5.2.3.4.4. Dosing Regimen
5.2.4. Recent Developments and Future Outlook
5.3. Arrowhead Pharmaceuticals
5.3.1. Company Overview
5.3.2. Management Team
5.3.3. Product Portfolio
5.3.3.1. Olpasiran
5.3.3.1.1. Drug Overview
5.3.3.1.2. Clinical Trial Information
5.3.3.1.3. Clinical Trial Results
5.3.3.1.4. Dosing Regimen
5.3.3.2. ARO-AAT
5.3.3.2.1. Drug Overview
5.3.3.2.2. Clinical Trial Information
5.3.3.2.3. Clinical Trial Results
5.3.3.2.4. Dosing Regimen
5.3.3.3. ARO-APOC3
5.3.3.3.1. Drug Overview
5.3.3.3.2. Clinical Trial Information
5.3.3.3.3. Clinical Trial Results
5.3.3.3.4. Dosing Regimen
5.3.4. Recent Developments and Future Outlook
5.4. Dicerna Pharmaceuticals
5.4.1. Company Overview
5.4.2. Management Team
5.4.3. Product Portfolio
5.4.3.1. Nedosiran
5.4.3.1.1 Drug Overview
5.4.3.1.2. Clinical Trial Information
5.4.3.1.3. Clinical Trial Results
5.4.3.1.4. Dosing Regimen
5.4.4. Recent Developments and Future Outlook
5.5. Geron
5.5.1. Company Overview
5.5.2. Management Team
5.5.3. Product Portfolio
5.5.3.1. Imtelstat
5.5.3.1.1. Drug Overview
5.5.3.1.2. Clinical Trial Information
5.5.3.1.3. Clinical Trial Results
5.5.3.1.4. Dosing Regimen
5.5.4. Recent Developments and Future Outlook
5.6. Ionis Pharmaceuticals
5.6.1. Company Overview
5.6.2. Management Team
5.6.3. Product Portfolio
5.6.3.1. Eplontersen
5.6.3.1.1 Drug Overview
5.6.3.1.2. Clinical Trial Information
5.6.3.1.3. Clinical Trial Results
5.6.3.1.4. Dosing Regimen
5.6.3.2. Olezarsen
5.6.3.2.1. Drug Overview
5.6.3.2.2. Clinical Trial Information
5.6.3.2.3. Clinical Trial Results
5.6.3.2.4. Dosing Regimen
5.6.3.3. Pelacarsen
5.6.3.3.1. Drug Overview
5.6.3.3.2. Clinical Trial Information
5.6.3.3.3. Clinical Trial Results
5.6.3.3.4. Dosing Regimen
5.6.3.3.5. Estimated Sales
5.6.3.4. Donidalorsen
5.6.3.4.1 Drug Overview
5.6.3.4.2. Clinical Trial Information
5.6.3.4.3. Clinical Trial Results
5.6.3.4.4. Dosing Regimen
5.6.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Drug Conjugates: Clinical Trial Analysis
6.2.1. Analysis by Trial Registration Year
6.2.2. Analysis by Trial Phase
6.2.3. Analysis by Trial Status
6.2.4. Analysis by Therapeutic Area
6.2.5. Analysis by Primary Purpose
6.2.6. Analysis by Age Group
6.2.7. Analysis by Type of Sponsor
6.2.8. Most Active Industry Players: Analysis by Number of Trials
6.2.9. Leading Drug Candidates: Analysis by Number of Trials
6.2.10. Analysis by Trial Registration Year and Trial Location
6.2.11. Analysis by Trial Registration Year and Enrolled Patient Population
6.2.12. Analysis by Trial Phase and Enrolled Patient Population
6.2.13. Analysis by Trial Status and Enrolled Patient Population
6.2.14. Analysis by Trial Location and Enrolled Patient Population
6.2.15. Analysis by Trial Status and Trial Location
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Partnership Models
7.2. Next Generation Drug Conjugates: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Analysis by Type of Partner and Parent Company Size
7.3.8. Analysis by Therapeutic Area
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.3.10. Analysis by Geography
7.3.10.1. Analysis by Type of Geography (Region-wise)
7.3.10.2. Analysis by Type of Geography (Country-wise)
7.3.10.3. Intercontinental and Intracontinental Agreements
8. ACADEMIC GRANTS ANALYSIS
8.1. Methodology and Key Parameters
8.2. Next Generation Drug Conjugates: Academic Grants Analysis
8.2.1. Analysis by Year of Grant Award
8.2.2. Analysis by Amount Awarded
8.2.3. Analysis by Funding Institute Center
8.2.4. Analysis by Support Period
8.2.5. Analysis by Funding Institute Center and Support Period
8.2.6. Analysis by Type of Grant Application
8.2.7. Analysis by Purpose of Grant
8.2.8. Analysis by Activity Code
8.2.9. Analysis by Study Section
8.2.10. Popular NIH Departments: Analysis by Number of Grants
8.2.11. Analysis by Type of Recipient Organization
8.2.11.1. Popular Recipient Organizations: Analysis by Number of Grants
8.2.11.2. Popular Recipient Organizations: Analysis by Amount Awarded
8.2.12. Prominent Program Officers: Analysis by Number of Grants
8.2.13 Analysis by Location of Recipient Organizations
9. PUBLICATION ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Drug Conjugates: Publication Analysis
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Analysis by Type of Conjugate
9.2.4. Analysis by Target Indication
9.2.5. Analysis by Copyright Holder
9.2.6. Word Cloud: Emerging Focus Area
9.2.7. Most Active Publishers: Analysis by Number of Publications
9.2.8. Key Journals: Analysis by Number of Publications
9.2.9. Key Journals: Analysis by Impact Factor
10. DRUG FAILURE ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Next Generation Drug Conjugates: Drug Failure Analysis
10.2.1. Analysis by Status of Discontinuation
10.2.2. Analysis by Phase of Discontinuation
10.2.3. Analysis by Average Trial Year
10.2.4. Analysis by Type of Therapy
10.2.5. Analysis by Target Indication
10.2.6. Analysis by Reason for Drug Failure
11. SUCCESS PROTOCOL ANALYSIS
11.1. Methodology and Key Parameters
11.2. Key Assumptions and Scoring Criteria
11.3. Success Protocol Analysis
11.4. Assessment of Approved Next Generation Drug Conjugates: Harvey Ball Analysis
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Key Assumptions and Forecast Methodology
12.2. Next Generation Drug Conjugates Market, 2023-2035
12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035
12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035
12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035
12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, 2023-2035
12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035
12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
12.2.2.1 Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035
12.2.2.2 Next Generation Drug Conjugates Market for Peptides, 2023-2035
12.2.2.3 Next Generation Drug Conjugates Market for Lipids, 2023-2035
12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035
12.2.3.2. Next Generation Drug Conjugates Market for Drugs, 2023-2035
12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035
12.2.3.4 Next Generation Drug Conjugates Market for si-RNAs, 2023-2035
12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, 2023-2035
12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, 2023-2035
12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
12.2.5.1. Next Generation Intravenous Drug Conjugates Market, 2023-2035
12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035
12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035
12.2.6.3. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, 2023-2035
12.2.6.4. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035
12.2.6.5. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035
12.2.6.6. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035
12.2.6.7. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035
12.2.6.8. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035
12.2.5.9. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035
12.2.5.10. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035
12.2.5.11. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035
12.2.5.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035
12.2.5.13. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035
12.2.5.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035
12.2.5.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market in North America, 2023-2035
12.2.6.1.1. Next Generation Drug Conjugates Market in the US, 2022-2035
12.2.6.1.2. Next Generation Drug Conjugates Market in Canada, 2022-2035
12.2.6.2. Next Generation Drug Conjugates Market in Europe, 2023-2035
12.2.6.2.1. Next Generation Drug Conjugates Market in the UK, 2022-2035
12.2.6.2.2. Next Generation Drug Conjugates Market in France, 2022-2035
12.2.6.2.3. Next Generation Drug Conjugates Market in Germany, 2022-2035
12.2.6.2.4. Next Generation Drug Conjugates Market in Spain, 2022-2035
12.2.6.2.5. Next Generation Drug Conjugates Market in Italy, 2022-2035
12.2.6.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035
12.2.6.3. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035
12.2.6.3.1. Next Generation Drug Conjugates Market in Japan, 2023-2035
12.2.6.3.2. Next Generation Drug Conjugates Market in Australia, 2023-2035
12.2.6.3.3. Next Generation Drug Conjugates Market in Brazil, 2023-2035
12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
12.3.1. Lutathera®
12.3.1.1. Sales Forecast (USD Million)
12.3.1.2. Net Present Value (USD Million)
12.3.1.3. Value Creation Analysis
12.3.2. Pluvicto®
12.3.2.1. Sales Forecast (USD Million)
12.3.2.2. Net Present Value (USD Million)
12.3.2.3. Value Creation Analysis
12.3.3. Givlaari®
12.3.3.1. Sales Forecast (USD Million)
12.3.3.2. Net Present Value (USD Million)
12.3.3.3. Value Creation Analysis
12.3.4. Oxlumo®
12.3.4.1. Sales Forecast (USD Million)
12.3.4.2. Net Present Value (USD Million)
12.3.4.3. Value Creation Analysis
12.3.5. Leqvio®
12.3.5.1. Sales Forecast (USD Million)
12.3.5.2. Net Present Value (USD Million)
12.3.5.3. Value Creation Analysis
12.3.6. Amvuttra®
12.3.6.1. Sales Forecast (USD Million)
12.3.6.2. Net Present Value (USD Million)
12.3.6.3. Value Creation Analysis
12.3.7. Eplontersen
12.3.7.1. Sales Forecast (USD Million)
12.3.7.2. Net Present Value (USD Million)
12.3.7.3. Value Creation Analysis
12.3.8. Olezarsen
12.3.8.1. Sales Forecast (USD Million)
12.3.8.2. Net Present Value (USD Million)
12.3.8.3. Value Creation Analysis
12.3.9. Pelacarsen
12.3.9.1. Sales Forecast (USD Million)
12.3.9.2. Net Present Value (USD Million)
12.3.9.3. Value Creation Analysis
12.3.10. Donidalorsen
12.3.10.1. Sales Forecast (USD Million)
12.3.10.2. Net Present Value (USD Million)
12.3.10.3. Value Creation Analysis
12.3.11. Fitusiran
12.3.11.1. Sales Forecast (USD Million)
12.3.11.2. Net Present Value (USD Million)
12.3.11.3. Value Creation Analysis
12.3.12. Nedosiran
12.3.12.1. Sales Forecast (USD Million)
12.3.12.2. Net Present Value (USD Million)
12.3.12.3. Value Creation Analysis
12.3.13. Imetlestat
12.3.13.1. Sales Forecast (USD Million)
12.3.13.2. Net Present Value (USD Million)
12.3.13.3. Value Creation Analysis
12.3.14. Olpasiran
12.3.14.1. Sales Forecast (USD Million)
12.3.14.2. Net Present Value (USD Million)
12.3.14.3. Value Creation Analysis
12.3.15. ARO-AAT
12.3.15.1. Sales Forecast (USD Million)
12.3.15.2. Net Present Value (USD Million)
12.3.15.3. Value Creation Analysis
12.3.16. ARO-APOC3
12.3.16.1. Sales Forecast (USD Million)
12.3.16.2. Net Present Value (USD Million)
12.3.16.3. Value Creation Analysis
12.3.17. ANG-1005
12.3.17.1. Sales Forecast (USD Million)
12.3.17.2. Net Present Value (USD Million)
12.3.17.3. Value Creation Analysis
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Next Generation Drug Conjugates Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Next Generation Drug Conjugates
3.2. Key Historical Events
3.3. Structure of Next Generation Drug Conjugates
3.4. Biochemical Interaction and Mechanism of Action
3.5. Key Target Indications
3.6. Advantages of Next Generation Drug Conjugates
3.7 Challenges associated with Next Generation Drug Conjugates
3.8. Future Perspectives
4. MARKET LANDSCAPE
4.1. Methodology
4.2. Next Generation Drug Conjugates: List of Therapies
4.2.1. Analysis by Type of Conjugate
4.2.2. Analysis by Type of Targeting Ligand
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Biological Target
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Stage of Development
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Type of Therapy
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Target Disease Indication
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Target Population
4.2.13. Analysis by Type of Conjugate and Stage of Development
4.2.14. Analysis by Type of Conjugate and Target Populatio
4.3 Next Generation Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.3.6. Most Active Players: Analysis by Number of Drug Candidates
5. COMPANY AND DRUG PROFILES
5.1. Advanced Accelerator Applications
5.1.1. Company Overview
5.1.2. Management Team
5.1.3. Product Portfolio
5.1.3.1. Lutathera®
5.1.3.1.1 Drug Overview
5.1.3.1.2. Clinical Trial Information
5.1.3.1.3. Clinical Trial Results
5.1.3.1.4. Dosing Regimen
5.1.3.1.5. Estimated Sales
5.1.3.2. Pluvicto®
5.1.3.2.1 Drug Overview
5.1.3.2.2. Clinical Trial Information
5.1.3.2.3. Clinical Trial Results
5.1.3.2.4. Dosing Regimen
5.1.3.2.5. Estimated Sales
5.1.4. Recent Developments and Future Outlook
5.2. Alnylam Pharmaceuticals
5.2.1. Company Overview
5.2.2. Management Team
5.2.3. Product Portfolio
5.2.3.1. Givlaari®
5.2.3.1.1. Drug Overview
5.2.3.1.2. Clinical Trial Information
5.2.3.1.3. Clinical Trial Results
5.2.4.1.4. Dosing Regimen
5.2.3.2. Oxlumo®
5.2.3.2.1. Drug Overview
5.2.3.2.2. Clinical Trial Information
5.2.3.2.3. Clinical Trial Results
5.2.3.2.4. Dosing Regimen
5.2.3.3. Leqvio®
5.2.3.3.1. Drug Overview
5.2.3.3.2. Clinical Trial Information
5.2.3.3.3. Clinical Trial Results
5.2.3.3.4. Dosing Regimen
5.2.3.4. Amvuttra®
5.2.3.4.1. Drug Overview
5.2.3.4.2. Clinical Trial Information
5.2.3.4.3. Clinical Trial Results
5.2.3.4.4. Dosing Regimen
5.2.4. Recent Developments and Future Outlook
5.3. Arrowhead Pharmaceuticals
5.3.1. Company Overview
5.3.2. Management Team
5.3.3. Product Portfolio
5.3.3.1. Olpasiran
5.3.3.1.1. Drug Overview
5.3.3.1.2. Clinical Trial Information
5.3.3.1.3. Clinical Trial Results
5.3.3.1.4. Dosing Regimen
5.3.3.2. ARO-AAT
5.3.3.2.1. Drug Overview
5.3.3.2.2. Clinical Trial Information
5.3.3.2.3. Clinical Trial Results
5.3.3.2.4. Dosing Regimen
5.3.3.3. ARO-APOC3
5.3.3.3.1. Drug Overview
5.3.3.3.2. Clinical Trial Information
5.3.3.3.3. Clinical Trial Results
5.3.3.3.4. Dosing Regimen
5.3.4. Recent Developments and Future Outlook
5.4. Dicerna Pharmaceuticals
5.4.1. Company Overview
5.4.2. Management Team
5.4.3. Product Portfolio
5.4.3.1. Nedosiran
5.4.3.1.1 Drug Overview
5.4.3.1.2. Clinical Trial Information
5.4.3.1.3. Clinical Trial Results
5.4.3.1.4. Dosing Regimen
5.4.4. Recent Developments and Future Outlook
5.5. Geron
5.5.1. Company Overview
5.5.2. Management Team
5.5.3. Product Portfolio
5.5.3.1. Imtelstat
5.5.3.1.1. Drug Overview
5.5.3.1.2. Clinical Trial Information
5.5.3.1.3. Clinical Trial Results
5.5.3.1.4. Dosing Regimen
5.5.4. Recent Developments and Future Outlook
5.6. Ionis Pharmaceuticals
5.6.1. Company Overview
5.6.2. Management Team
5.6.3. Product Portfolio
5.6.3.1. Eplontersen
5.6.3.1.1 Drug Overview
5.6.3.1.2. Clinical Trial Information
5.6.3.1.3. Clinical Trial Results
5.6.3.1.4. Dosing Regimen
5.6.3.2. Olezarsen
5.6.3.2.1. Drug Overview
5.6.3.2.2. Clinical Trial Information
5.6.3.2.3. Clinical Trial Results
5.6.3.2.4. Dosing Regimen
5.6.3.3. Pelacarsen
5.6.3.3.1. Drug Overview
5.6.3.3.2. Clinical Trial Information
5.6.3.3.3. Clinical Trial Results
5.6.3.3.4. Dosing Regimen
5.6.3.3.5. Estimated Sales
5.6.3.4. Donidalorsen
5.6.3.4.1 Drug Overview
5.6.3.4.2. Clinical Trial Information
5.6.3.4.3. Clinical Trial Results
5.6.3.4.4. Dosing Regimen
5.6.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Drug Conjugates: Clinical Trial Analysis
6.2.1. Analysis by Trial Registration Year
6.2.2. Analysis by Trial Phase
6.2.3. Analysis by Trial Status
6.2.4. Analysis by Therapeutic Area
6.2.5. Analysis by Primary Purpose
6.2.6. Analysis by Age Group
6.2.7. Analysis by Type of Sponsor
6.2.8. Most Active Industry Players: Analysis by Number of Trials
6.2.9. Leading Drug Candidates: Analysis by Number of Trials
6.2.10. Analysis by Trial Registration Year and Trial Location
6.2.11. Analysis by Trial Registration Year and Enrolled Patient Population
6.2.12. Analysis by Trial Phase and Enrolled Patient Population
6.2.13. Analysis by Trial Status and Enrolled Patient Population
6.2.14. Analysis by Trial Location and Enrolled Patient Population
6.2.15. Analysis by Trial Status and Trial Location
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Partnership Models
7.2. Next Generation Drug Conjugates: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Partner
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Analysis by Type of Partner and Parent Company Size
7.3.8. Analysis by Therapeutic Area
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.3.10. Analysis by Geography
7.3.10.1. Analysis by Type of Geography (Region-wise)
7.3.10.2. Analysis by Type of Geography (Country-wise)
7.3.10.3. Intercontinental and Intracontinental Agreements
8. ACADEMIC GRANTS ANALYSIS
8.1. Methodology and Key Parameters
8.2. Next Generation Drug Conjugates: Academic Grants Analysis
8.2.1. Analysis by Year of Grant Award
8.2.2. Analysis by Amount Awarded
8.2.3. Analysis by Funding Institute Center
8.2.4. Analysis by Support Period
8.2.5. Analysis by Funding Institute Center and Support Period
8.2.6. Analysis by Type of Grant Application
8.2.7. Analysis by Purpose of Grant
8.2.8. Analysis by Activity Code
8.2.9. Analysis by Study Section
8.2.10. Popular NIH Departments: Analysis by Number of Grants
8.2.11. Analysis by Type of Recipient Organization
8.2.11.1. Popular Recipient Organizations: Analysis by Number of Grants
8.2.11.2. Popular Recipient Organizations: Analysis by Amount Awarded
8.2.12. Prominent Program Officers: Analysis by Number of Grants
8.2.13 Analysis by Location of Recipient Organizations
9. PUBLICATION ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Drug Conjugates: Publication Analysis
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Analysis by Type of Conjugate
9.2.4. Analysis by Target Indication
9.2.5. Analysis by Copyright Holder
9.2.6. Word Cloud: Emerging Focus Area
9.2.7. Most Active Publishers: Analysis by Number of Publications
9.2.8. Key Journals: Analysis by Number of Publications
9.2.9. Key Journals: Analysis by Impact Factor
10. DRUG FAILURE ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. Next Generation Drug Conjugates: Drug Failure Analysis
10.2.1. Analysis by Status of Discontinuation
10.2.2. Analysis by Phase of Discontinuation
10.2.3. Analysis by Average Trial Year
10.2.4. Analysis by Type of Therapy
10.2.5. Analysis by Target Indication
10.2.6. Analysis by Reason for Drug Failure
11. SUCCESS PROTOCOL ANALYSIS
11.1. Methodology and Key Parameters
11.2. Key Assumptions and Scoring Criteria
11.3. Success Protocol Analysis
11.4. Assessment of Approved Next Generation Drug Conjugates: Harvey Ball Analysis
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Key Assumptions and Forecast Methodology
12.2. Next Generation Drug Conjugates Market, 2023-2035
12.2.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate, 2023 and 2035
12.2.1.1. Next Generation Drug Conjugates Market for Peptide Radionuclide Conjugates, 2023-2035
12.2.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Anti Sense Medicine, 2023-2035
12.2.1.3. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, 2023-2035
12.2.1.4. Next Generation Drug Conjugates Market for Peptide Drug Conjugates, 2023-2035
12.2.2. Next Generation Drug Conjugates Market: Distribution by Targeting Ligand
12.2.2.1 Next Generation Drug Conjugates Market for Amino Sugars, 2023-2035
12.2.2.2 Next Generation Drug Conjugates Market for Peptides, 2023-2035
12.2.2.3 Next Generation Drug Conjugates Market for Lipids, 2023-2035
12.2.3. Next Generation Drug Conjugates Market: Distribution by Payload
12.2.3.1. Next Generation Drug Conjugates Market for Radionuclides, 2023-2035
12.2.3.2. Next Generation Drug Conjugates Market for Drugs, 2023-2035
12.2.3.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, 2023-2035
12.2.3.4 Next Generation Drug Conjugates Market for si-RNAs, 2023-2035
12.2.4. Next Generation Drug Conjugates Market: Distribution by Therapy
12.2.4.1. Next Generation Drug Conjugates Market for Monotherapy, 2023-2035
12.2.4.2. Next Generation Drug Conjugates Market for Combination Therapy, 2023-2035
12.2.5. Next Generation Drug Conjugates Market: Distribution by Route of Administration
12.2.5.1. Next Generation Intravenous Drug Conjugates Market, 2023-2035
12.2.5.2. Next Generation Subcutaneous Drug Conjugates Market, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market for Gastroenteropancreatic Neuroendocrine Tumors, 2023-2035
12.2.6.2. Next Generation Drug Conjugates Market for Prostate Cancer, 2023-2035
12.2.6.3. Next Generation Drug Conjugates Market for Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, 2023-2035
12.2.6.4. Next Generation Drug Conjugates Market for Hereditary Transthyretin Amyloidosis, 2023-2035
12.2.6.5. Next Generation Drug Conjugates Market for Atherosclerotic Cardiovascular Diseases, 2023-2035
12.2.6.6. Next Generation Drug Conjugates Market for Severe Hypertriglyceridemia, 2023-2035
12.2.6.7. Next Generation Drug Conjugates Market for Hereditary Angioedema, 2023-2035
12.2.6.8. Next Generation Drug Conjugates Market for Acute Hepatic Porphyria, 2023-2035
12.2.5.9. Next Generation Drug Conjugates Market for Primary Hyperoxaluria, 2023-2035
12.2.5.10. Next Generation Drug Conjugates Market for Heterozygous Familial Hypercholesterolemia, 2023-2035
12.2.5.11. Next Generation Drug Conjugates Market for Hemophilia, 2023-2035
12.2.5.12. Next Generation Drug Conjugates Market for Low-Risk Myelodysplastic Syndrome, 2023-2035
12.2.5.13. Next Generation Drug Conjugates Market for Myelofibrosis, 2023-2035
12.2.5.14. Next Generation Drug Conjugates Market for Alpha-1 Antitrypsin Deficiency Liver Disease, 2023-2035
12.2.5.15. Next Generation Drug Conjugates Market for Familial Chylomicronemia Syndrome, 2023-2035
12.2.6. Next Generation Drug Conjugates Market: Distribution by Key Geographical Regions, 2023 and 2035
12.2.6.1. Next Generation Drug Conjugates Market in North America, 2023-2035
12.2.6.1.1. Next Generation Drug Conjugates Market in the US, 2022-2035
12.2.6.1.2. Next Generation Drug Conjugates Market in Canada, 2022-2035
12.2.6.2. Next Generation Drug Conjugates Market in Europe, 2023-2035
12.2.6.2.1. Next Generation Drug Conjugates Market in the UK, 2022-2035
12.2.6.2.2. Next Generation Drug Conjugates Market in France, 2022-2035
12.2.6.2.3. Next Generation Drug Conjugates Market in Germany, 2022-2035
12.2.6.2.4. Next Generation Drug Conjugates Market in Spain, 2022-2035
12.2.6.2.5. Next Generation Drug Conjugates Market in Italy, 2022-2035
12.2.6.2.6. Next Generation Drug Conjugates Market in Rest of the Europe, 2022-2035
12.2.6.3. Next Generation Drug Conjugates Market in Asia-Pacific and Rest of the World, 2023-2035
12.2.6.3.1. Next Generation Drug Conjugates Market in Japan, 2023-2035
12.2.6.3.2. Next Generation Drug Conjugates Market in Australia, 2023-2035
12.2.6.3.3. Next Generation Drug Conjugates Market in Brazil, 2023-2035
12.3. Next Generation Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
12.3.1. Lutathera®
12.3.1.1. Sales Forecast (USD Million)
12.3.1.2. Net Present Value (USD Million)
12.3.1.3. Value Creation Analysis
12.3.2. Pluvicto®
12.3.2.1. Sales Forecast (USD Million)
12.3.2.2. Net Present Value (USD Million)
12.3.2.3. Value Creation Analysis
12.3.3. Givlaari®
12.3.3.1. Sales Forecast (USD Million)
12.3.3.2. Net Present Value (USD Million)
12.3.3.3. Value Creation Analysis
12.3.4. Oxlumo®
12.3.4.1. Sales Forecast (USD Million)
12.3.4.2. Net Present Value (USD Million)
12.3.4.3. Value Creation Analysis
12.3.5. Leqvio®
12.3.5.1. Sales Forecast (USD Million)
12.3.5.2. Net Present Value (USD Million)
12.3.5.3. Value Creation Analysis
12.3.6. Amvuttra®
12.3.6.1. Sales Forecast (USD Million)
12.3.6.2. Net Present Value (USD Million)
12.3.6.3. Value Creation Analysis
12.3.7. Eplontersen
12.3.7.1. Sales Forecast (USD Million)
12.3.7.2. Net Present Value (USD Million)
12.3.7.3. Value Creation Analysis
12.3.8. Olezarsen
12.3.8.1. Sales Forecast (USD Million)
12.3.8.2. Net Present Value (USD Million)
12.3.8.3. Value Creation Analysis
12.3.9. Pelacarsen
12.3.9.1. Sales Forecast (USD Million)
12.3.9.2. Net Present Value (USD Million)
12.3.9.3. Value Creation Analysis
12.3.10. Donidalorsen
12.3.10.1. Sales Forecast (USD Million)
12.3.10.2. Net Present Value (USD Million)
12.3.10.3. Value Creation Analysis
12.3.11. Fitusiran
12.3.11.1. Sales Forecast (USD Million)
12.3.11.2. Net Present Value (USD Million)
12.3.11.3. Value Creation Analysis
12.3.12. Nedosiran
12.3.12.1. Sales Forecast (USD Million)
12.3.12.2. Net Present Value (USD Million)
12.3.12.3. Value Creation Analysis
12.3.13. Imetlestat
12.3.13.1. Sales Forecast (USD Million)
12.3.13.2. Net Present Value (USD Million)
12.3.13.3. Value Creation Analysis
12.3.14. Olpasiran
12.3.14.1. Sales Forecast (USD Million)
12.3.14.2. Net Present Value (USD Million)
12.3.14.3. Value Creation Analysis
12.3.15. ARO-AAT
12.3.15.1. Sales Forecast (USD Million)
12.3.15.2. Net Present Value (USD Million)
12.3.15.3. Value Creation Analysis
12.3.16. ARO-APOC3
12.3.16.1. Sales Forecast (USD Million)
12.3.16.2. Net Present Value (USD Million)
12.3.16.3. Value Creation Analysis
12.3.17. ANG-1005
12.3.17.1. Sales Forecast (USD Million)
12.3.17.2. Net Present Value (USD Million)
12.3.17.3. Value Creation Analysis
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
